Evolution of the Average Target: Gilead Sciences, Inc.

Evolution of the Target Price: Gilead Sciences, Inc.

Changes in Analyst Recommendations: Gilead Sciences, Inc.

ec.IRQ54V_Z1qyxe-P1E1x3_CwVuRWTtRCem7MLubl0oPE.UEcIqBrosNmEFYWmIj4ol39P_Hz1-CLK6oRq09wg98N5XHXZFp2yxfcwrg~ce5ebf0f90c1782a979d0ad5b6082585
07-08 Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says MT
07-08 Morgan Stanley Adjusts Price Target Gilead Sciences to $166 From $168, Maintains Overweight Rating MT
07-07 Truist Securities Adjusts Gilead Sciences Price Target to $156 From $157 MT
07-07 RBC Capital Adjusts Gilead Sciences Price Target to $120 From $122, Maintains Sector Perform Rating MT
07-06 Analyst recommendations: Chubb, Delta Air Lines, Pfizer, AMD, Dow… Zonebourse
07-06 HSBC Upgrades Gilead Sciences to Buy From Hold, Adjusts Price Target to $155 From $133 MT
06-08 Gilead Sciences Faces Potential Threat From In Vivo CAR-T, RBC Says MT
05-20 Maxim Upgrades Gilead Sciences to Buy From Hold, Price Target is $165 MT
05-19 Daiwa Securities Adjusts PT on Gilead Sciences to $150 From $161, Maintains Outperform Rating MT
05-11 Gilead's Emvistegrast Readout Unlikely to Move Stock, RBC Says MT
05-11 Rothschild & Co Redburn Adjusts Price Target on Gilead Sciences to $167 From $170 MT
05-08 Leerink Partners Adjusts Price Target on Gilead Sciences to $146 From $148 MT
05-08 Gilead Sciences' Increased Yeztugo Guidance is 'Good Enough' for the Stock, Morgan Stanley Says MT
05-08 Morgan Stanley Adjusts Price Target on Gilead Sciences to $168 From $175 MT
04-28 Morgan Stanley Adjusts Gilead Sciences Price Target to $175 From $171, Maintains Overweight Rating MT
04-17 Goldman Sachs Adjusts Gilead Sciences Price Target to $130 From $125, Maintains Neutral Rating MT
04-17 Cantor Fitzgerald Adjusts Price Target on Gilead Sciences to $155 From $115, Maintains Overweight Rating MT
04-13 Citigroup Adjusts Gilead Sciences PT to $165 From $156, Maintains Buy Rating MT
04-10 Cantor Fitzgerald Adjusts Price Target on Gilead Sciences to $115 From $155, Maintains Overweight Rating MT
04-08 Gilead Sciences' Tubulis Buy Underscores Shift Beyond HIV, Oppenheimer Says MT
04-07 RBC Adjusts Price Target on Gilead Sciences to $123 From $118, Maintains Sector Perform Rating MT
03-31 Gilead Sciences Shows Solid Early Yeztugo Persistence but Limited Market Expansion, RBC Says MT
02-25 Daiwa Securities Adjusts Price Target on Gilead Sciences to $161 From $129, Maintains Outperform Rating MT
02-25 Analyst recommendations: IBM, Axon, Caterpillar, Fair Isaac, Gilead… Zonebourse
02-24 Gilead Sciences Acquiring Arcellx to Consolidate Anito-Cel Ownership, UBS Securities Says MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
- - - -
+2.03%
-1.83%
+2.21%
+7.26%
+14.04%
-1%
-1.93%
-3.54%
+20.28%
Average +4.17%
Weighted average by Cap. +2.74%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
134.84USD
Average target price
158.30USD
Spread / Average Target
+17.40%
High Price Target
180.00USD
Spread / Highest target
+33.49%
Low Price Target
120.00USD
Spread / Lowest Target
-11.01%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Morgan Stanley
Truist Securities
RBC Capital Markets
HSBC
Maxim
Daiwa Securities
Rothschild & Co Redburn
Leerink Partners
Goldman Sachs
Cantor Fitzgerald
Citigroup
Barclays
Argus
Mizuho Securities
Wolfe Research
TD Cowen
Deutsche Bank Securities
Baird
Scotiabank
Bernstein
BMO Capital
Needham & Co.
Oppenheimer
JPMorgan Chase
Wells Fargo Securities
UBS
DBS Bank
BofA Securities
Jefferies & Co.
Redburn Atlantic
Piper Sandler
Raymond James
SVB Securities LLC
Cowen
SVB Leerink
Credit Suisse
Redburn
DZ BANK Elmar Kraus
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
134.84USD
Average target price
158.30USD
Spread / Average Target
+17.40%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GILD Stock
  4. GILD34 Stock
  5. Consensus Gilead Sciences, Inc.